Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
- Conditions
- Follicular Lymphoma
- Interventions
- Drug: Rituximab-CHOPDrug: Rituximab-CVPDrug: Rituximab-Bendamustine
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1030
- Registration Number
- NCT01476787
- Locations
- 🇺🇸
Local Institution - 54103, Chandler, Arizona, United States
🇺🇸Local Institution - 51803, Fullerton, California, United States
🇺🇸Local Institution - 52003, Los Angeles, California, United States
A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 33
- Registration Number
- NCT01474330
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 5
- Registration Number
- NCT01466725
- Locations
- 🇺🇸
Dermatology and Research, Dallas, Texas, United States
🇺🇸Advanced Pharma, CR, LLC, Miami, Florida, United States
🇺🇸University of Miami - Department of Dermatology, Miami, Florida, United States
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Celgene
- Target Recruit Count
- 51
- Registration Number
- NCT01456039
- Locations
- 🇯🇵
Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan
🇯🇵Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
- Conditions
- Multiple MyelomaLymphoma, Large B-Cell, DiffusePrimary Central Nervous System LymphomaGlioblastomaPleiotropic Pathway ModifierLymphoma
- Interventions
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 271
- Registration Number
- NCT01421524
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey University, New Brunswick, New Jersey, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸Texas Oncology, PA - Dallas 75246, Dallas, Texas, United States
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaAcute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 88
- Registration Number
- NCT01358734
- Locations
- 🇺🇸
(240) Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸(160) The Western Pennsylvania Hospital- Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸(200) Coastal Integrative Cancer Care, San Luis Obispo, California, United States
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 19
- Registration Number
- NCT01353664
- Locations
- 🇬🇧
Sarah Cannon Research UK, London, United Kingdom
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
- Conditions
- Glioblastoma MultiformeSquamous Cell Carcinoma of Head and NeckProstate CancerEwing's OsteosarcomaNeoplasm MetastasisChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Celgene
- Target Recruit Count
- 118
- Registration Number
- NCT01353625
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇩🇪Universitatsklinikum Wurzburg, Würzburg, Germany
🇺🇸UCLA, Los Angeles, California, United States
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
- Conditions
- Chronic Lymphocytic LeukemiaWaldenstrom MacroglobulinemiaB Cell Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 113
- Registration Number
- NCT01351935
- Locations
- 🇺🇸
University of Arizona SPORE, Tucson, Arizona, United States
🇺🇸Clearview Cancer Institute Oncology Specialties, P.C, Huntsville, Alabama, United States
🇺🇸University of California San Diego, La Jolla, California, United States
MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry
- Conditions
- Myelodysplastic Syndrome
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 149
- Registration Number
- NCT01347944
- Locations
- 🇮🇹
Dipartimento Onco - Ematologico Azienda Ospedaliera SS Antonio, Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹Ematologia Azienda Ospedaliera Universitaria Policlinico di Bari, Bari, Italy
🇮🇹Ematologia A.O. Ospedale Riuniti di Bergamo, Bergamo, Italy